Prognostic Significance of Inner Quadrant Involvement in Breast Cancer Treated with Neoadjuvant Chemotherapy

다국어 초록 (Multilingual Abstract)

Purpose: In the present study, we aimed to evaluate the initial tumor location as a prognostic factor in breast cancer patients treated with neoadjuvant chemotherapy (NAC). Methods: Between March 2002 and January 2007, a total of 179 patients with stage II/III breast cancer underwent NAC followed by breast surgery. Using physical and radiologic findings, patients were grouped by their initial tumor location into inner/both quadrant (upper/lower inner quadrant involvement +/– multicentric tumor involving outer quadrant; n=97) and outer quadrant (n=82) tumor groups. All patients received neoadjuvant docetaxel/doxorubicin chemotherapy. One hundred two patients underwent modified radical mastectomy and 77 patients underwent breastconserving surgery. Adjuvant radiotherapy (RT) and hormonal therapy were administered after surgery when indicated. While 156 patients underwent postoperative RT, 23 did not. The median follow-up duration was 61.1 (12–106) months. Results: The 5-year disease-free survival (DFS) and overall survival rates of all patients were 74.8% and 89.9%, respectively. Patients with inner/ both quadrant tumors had lower 5-year DFS than those with outer quadrant tumors (67.7% vs. 83.4%, respectively; hazard ratio [HR]=1.941, p=0.034). A nodal ratio >25% was also an independent adverse prognostic factor for DFS (HR=3.276; p<0.001). There was no significant difference in DFS (p=0.592) after RT on the internal mammary node (IMN). Treatment failed in 44 out of 179 patients (24.6%), of which 27 patients had inner/ both quadrant tumors. Twenty-one out of 27 patients had distant failures. Conclusion: Among breast cancer patients treated with NAC, those with inner/both quadrant tumors had lower DFS than those with outer quadrant tumors. More aggressive neoadjuvant and/or adjuvant chemotherapy with IMN RT is required for improved disease control and long-term survival.

참고문헌 (Reference)

1 Turner-Warwick RT, "The lymphatics of the breast" 46 : 574-582, 1959

2 Buchholz TA, "Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference" 26 : 791-797, 2008

3 Lohrisch C, "Relationship between tumor location and relapse in 6,781 women with early invasive breast cancer" 18 : 2828-2835, 2000

4 Lim ST, "Prognostic implication of the tumor location according to molecular subtypes in axillary lymph node-positive invasive ductal cancer in a Korean population" 156 : 473-483, 2016

5 Keam B, "Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer" 7 : 203-, 2007

6 김세현, "Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study" 대한암학회 48 (48): 1373-1381, 2016

7 Gralow JR, "Preoperative therapy in invasive breast cancer:pathologic assessment and systemic therapy issues in operable disease" 26 : 814-819, 2008

8 Haffty BG, "Patterns of local-regional management following neoadjuvant chemotherapy in breast cancer: results from ACOSOG Z1071 (Alliance)" 94 : 493-502, 2016

9 Reitsamer R, "Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer" 16 : 867-870, 2005

10 Mauri D, "Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis" 97 : 188-194, 2005

11 Smith IC, "Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel" 20 : 1456-1466, 2002

12 Bräutigam E, "Medial tumor localization in breast cancer: an unappreciated risk factor?" 185 : 663-668, 2009

13 Tsai J, "Lymph node ratio analysis after neoadjuvant chemotherapy is prognostic in hormone receptor-positive and triple-negative breast cancer" 23 : 3310-3316, 2016

14 Kim WH, "Location of triple-negative breast cancers: comparison with estrogen receptor-positive breast cancers on MR imaging" 10 : e0116344-, 2015

15 Chia S, "Locally advanced and inflammatory breast cancer" 26 : 786-790, 2008

16 Heuts EM, "Internal mammary lymph drainage and sentinel node biopsy in breast cancer: a study on 1008 patients" 35 : 252-257, 2009

17 Poortmans PM, "Internal mammary and medial Ssupraclavicular irradiation in breast cancer" 373 : 317-327, 2015

18 Farrús B, "Incidence of internal mammary node metastases after a sentinel lymph node technique in breast cancer and its implication in the radiotherapy plan" 60 : 715-721, 2004

19 Gonzalez-Angulo AM, "Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy" 23 : 7098-7104, 2005

20 Zucali R, "Early breast cancer: evaluation of the prognostic role of the site of the primary tumor" 16 : 1363-1366, 1998

21 Chung Y, "Dummy run of quality assurance program in a phase 3 randomized trial investigating the role of internal mammary lymph node irradiation in breast cancer patients: Korean Radiation Oncology Group 08-06 study" 91 : 419-426, 2015

22 Gaffney DK, "Diminished survival in patients with inner versus outer quadrant breast cancers" 21 : 467-472, 2003

23 Keam B, "Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy" 116 : 153-160, 2009

24 Huang O, "Breast cancer subpopulation with high risk of internal mammary lymph nodes metastasis:analysis of 2,269 Chinese breast cancer patients treated with extended radical mastectomy" 107 : 379-387, 2008